NCT07182552Enrolling By Invitation1 期
Phase I Clinical Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics of NTB003 in Healthy Participants
Nanjing Chia-tai Tianqing Pharmaceutical1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2025年6月30日最近更新:
干预措施
试验速览
- 阶段
- 1 期
- 状态
- Enrolling By Invitation
- 发起方
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Safety and tolerability, including the incidence of treatment-emergent adverse events (TEAEs), treatment-related TEAEs (TRAEs), and serious adverse events (SAEs)
研究概览
简要总结
This study is a randomized, double-blind, dose-escalation Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetic/pharmacodynamic characteristics of NTB003 injection in healthy volunteers.
详细描述
This study is a randomized, double-blind, dose-escalation Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetic/pharmacodynamic characteristics of NTB003 injection in healthy volunteers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
盲法说明
double-blind
入排标准
- 年龄范围
- 25 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •1. Ensure good communication with the Investigator, understand and comply with all requirements of the study, voluntarily participate in the trial, and sign the informed consent form.
- •2. participants aged between 25 and 45 inclusive at the time of signing the informed consent form.
- •3. Body mass index (BMI) is 19.0 kg/m2≤BMI≤26.0 kg/m2, and men must weigh ≥50 kg and women must weigh≥45 kg.
- •4. Physical health and do not have any clinical diseases (including respiratory system, circulatory system, digestive system, nervous system, blood system, genitourinary system, endocrine system diseases) or mental illness (including depression, schizophrenia, etc.) during the screening interview.
- •5. Physical examination, electrocardiogram, vital signs, laboratory and other related examinations are normal or abnormalities are of no clinical significance at screening.
- •6. Agree to use reliable contraceptive methods with their partners during the trial; female volunteers of childbearing age must have a negative pregnancy test before the first use of the study drug.
排除标准
- •Known or suspected allergy to the investigational drug or any of its components, or predisposition to allergy.
- •Previous treatment with any anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody.
- •Presence of scars, tattoos, moles, tenderness, bruising, erythema, induration, or damage at the intended injection site.
- •Difficulty with blood collection, inability to tolerate venous indwelling catheterization, or a history of syncope due to venipuncture.
- •Abnormal or did not have results for hepatitis B surface antigen, hepatitis C virus antibody, combined human immunodeficiency virus (HIV) antigen/antibody test, or Treponema pallidum antibody (TP-Ab).
- •History or suspected history of diabetes mellitus, or fasting blood glucose or glycated hemoglobin (HbA1c) above the upper limit of normal during screening.
- •History of ear diseases, ear surgery, hearing impairment, or a family history of hearing disorders.
- •History of thymic diseases such as thymoma or myasthenia gravis, or autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, or inflammatory bowel disease.
- •Use of any medications within 2 weeks prior to screening, including prescription drugs, over-the-counter drugs, herbal medicines, traditional Chinese medicines, and dietary supplements.
- •Any active or suspected bacterial, viral, or fungal infection within 4 weeks prior to screening, such as common cold, viral syndrome, influenza-like symptoms.
- •Receipt of live attenuated or inactivated vaccines within 4 weeks prior to screening, or planned vaccination with such vaccines during the study period.
- •Underwent surgical procedures within 3 months prior to screening, or plans to undergo surgery during the study period.
- •Participation in any other clinical trial and receipt of an investigational drug within 3 months prior to screening.
- •Blood donation or significant blood loss (>400 mL), receipt of blood transfusion or blood products within 3 months prior to screening, or plans to donate blood or blood components during the study or within 3 months after completion.
- •Current smoker or history of smoking more than 5 cigarettes per day within 3 months prior to screening, or inability to abstain from tobacco products during the study.
- •History of alcohol abuse or regular alcohol consumption within 6 months prior to screening, defined as more than 14 units of alcohol per week (1 unit = 360 mL beer, 45 mL spirits with 40% alcohol, or 150 mL wine); unwillingness to abstain from alcohol or alcohol-containing products during the study; or abnormal/unperformed breath alcohol test results.
- •History of drug abuse or use of soft drugs (e.g., cannabis) or hard drugs (e.g., cocaine, phencyclidine) within 1 year prior to screening; or positive/unperformed urine drug screening results.
- •Special dietary requirements incompatible with a standardized diet.
- •Occurrence of acute illness during the screening phase or prior to study drug administration.
- •Any other condition that, in the opinion of the investigator, may interfere with the study or make the subject unsuitable for participation.
研究组 & 干预措施
NTB003 dose 1, dose 2, dose 3, dose 4
Experimental
干预措施: NTB003 (Drug)
Placebo dose 1, dose 2, dose 3, dose 4
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Safety and tolerability, including the incidence of treatment-emergent adverse events (TEAEs), treatment-related TEAEs (TRAEs), and serious adverse events (SAEs)
时间窗: Day 0 up to 154 days for healthy participants
Safety and tolerability, including the incidence of treatment-emergent adverse events (TEAEs), treatment-related TEAEs (TRAEs), and serious adverse events (SAEs)
次要结局
- Pharmacokinetic parameter Tmax(Day 0 up to 154 days)
- Pharmacokinetic parameter Cmax(Day 0 up to 154 days)
- Pharmacokinetic parameter AUC(Day 0 up to 154 days)
- Pharmacokinetic parameter T1/2(Day 0 up to 154 days)
- Incidence of anti-drug antibody (ADA) development in NTB003 treated participants over time(Day 0 up to 154 days)
- PD indicator IGF-1 concentration and changes relative to baseline(Day 0 up to 154 days)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacokinetic of TQB3702 Tablets in Healthy Adult SubjectsSystemic Lupus ErythematosusNCT06448273Chia Tai Tianqing Pharmaceutical Group Co., Ltd.40
撤回
1 期
Clinical Trial to Assess Safety and Immunogenicity of a Synthetic Vaccine Against Streptococcus PyogenesRheumatic FeverNCT03998592Butantan Institute
已完成
1 期
A Clinical Study of AK115 in Healthy SubjectsHealthy VolunteersNCT05286970Akeso42
已完成
1 期
A Clinical Study to Evaluate MW33 InjectionCovid19NCT04533048Mabwell (Shanghai) Bioscience Co., Ltd.42
已完成
1 期
An Evaluation of 9MW1911 Injection in Healthy SubjectsCOPDAtopic DermatitisAsthmaNCT05803902Mabwell (Shanghai) Bioscience Co., Ltd.48